Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non–small cell lung cancer and idiopathic pulmonary fibrosis (IPF). This phase 1 open‐label study investigated the influence of mild and moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerab...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Main Authors: Marzin, Kristell, Kretschmar, Gunther, Luedtke, Doreen, Kraemer, Sandrine, Kuelzer, Raimund, Schlenker‐Herceg, Rozsa, Schmid, Ulrike, Schnell, David, Dallinger, Claudia
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Special Populations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836871/
https://ncbi.nlm.nih.gov/pubmed/29106740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1025
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares